2-吗啉-4-基乙基1-苯基环己烷-1-羧酸酯 | 138847-85-5

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 2-吗啉-4-基乙基1-苯基环己烷-1-羧酸酯
• 英文名称: 2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate
• 英文别名: 2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate
• CAS: 138847-85-5
• 化学式: C₁₉H₂₇NO₃
• 分子量: 317.4
• InChiKey: RQHKZUBCUZVZEF-UHFFFAOYSA-N

物化性质

• 沸点：
  446.6±40.0 °C(Predicted)
• 密度：
  1.103±0.06 g/cm3(Predicted)
• 溶解度：
  H2O: ≤24 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING A GROWTH RELATED DISEASE AND/OR A CLINICAL CONDITION THEREOF<br/>[FR] COMPOSITIONS ET MÉTHODES DE SUPPRESSION ET/OU DE TRAITEMENT D'UNE MALADIE LIÉE À LA CROISSANCE ET/OU DE SON ÉTAT CLINIQUE
  申请人：CK BIOTECHNOLOGY CO

  公开号：WO2020079570A1

  公开（公告）日：2020-04-23

  Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with growth or a related clinical condition thereof, are disclosed.

  本文揭示了包含一个或多个抑制CXXC5-DVL界面的药剂的治疗组合物，以及将这些治疗组合物用于模拟、治疗、减少对治疗的抵抗力、预防和诊断与生长或相关临床状况有关的疾病/疾病的方法。
• [EN] A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF<br/>[FR] COMPOSITIONS POLYMORPHES CRISTALLINES A2-73 DE MATIÈRE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ANAVEX LIFE SCIENCES CORP

  公开号：WO2019200345A1

  公开（公告）日：2019-10-17

  The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.

  本公开提供了自由基或盐形式的四氢-N，N-二甲基-2,2-二苯基-3-呋喃甲胺（A2-73）的晶体形式。还描述了包括所述晶体形式的制药配方和剂型，以及使用晶体A2-73的剂型进行神经保护的方法，包括治疗神经退行性和其他疾病。
• Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
  申请人：Köster Hubert

  公开号：US20110118136A1

  公开（公告）日：2011-05-19

  Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Each compound has the formula: wherein: Z is a trityl derivative; X, the reactivity function, covalently binds to amino acid side chains of proteins; Y, the selectivity function, modulates binding of X to the amino acid side chains in proteins such that X binds to fewer proteins when Y is present than in its absence; and Q permits separation or immobilization of the capture compound. Automated systems for performing the methods also are provided.

  本文提供了捕获化合物和化合物集合以及使用这些化合物进行生物分子分析的方法。特别地，提供了用于分析复杂蛋白质混合物（如蛋白质组）的集合、化合物和方法。这些化合物是多功能试剂，可用于分离和分离复杂蛋白质混合物。每个化合物的公式为：其中：Z是三苯甲基衍生物；X是反应性功能，共价结合到蛋白质的氨基酸侧链上；Y是选择性功能，调节X与蛋白质中氨基酸侧链的结合，使得在Y存在时，X与较少的蛋白质结合，而在Y不存在时，X与更多的蛋白质结合；Q允许分离或固定捕获化合物。本文还提供了用于执行这些方法的自动化系统。
• Use of Sigma-1 receptor agonist compounds
  申请人：MTA TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA

  公开号：US10124006B2

  公开（公告）日：2018-11-13

  The present invention is directed to compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. In particular, embodiments of the present invention relate to the use of Sigma-1 receptor agonists for use in the treatment or prevention of progressive fibrosis characterized by the overproliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1-receptor agonists are disclosed.

  本发明涉及用于预防、抑制和/或治疗各种纤维增生性疾病中出现的进行性纤维化的组合物和方法。特别是，本发明的实施方案涉及 Sigma-1 受体激动剂在治疗或预防进行性纤维化中的用途，进行性纤维化的特征是 ECM 生成细胞（如肌成纤维细胞）的过度增殖以及医疗或疾病条件下 ECM 成分的过度沉积。本文公开了优选的 Sigma-1 受体激动剂。
• Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
  申请人：DREXEL UNIVERSITY

  公开号：US10314795B2

  公开（公告）日：2019-06-11

  The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.

  本发明包括可用于预防、治疗或改善西格玛相关紊乱或疾病的化合物。本发明的化合物可调节细胞蛋白质的平衡，其中包括：蛋白质的翻译起始、折叠、加工、运输和降解（包括泛素选择性自噬）。本发明还包括预防、治疗或改善有需要的受试者与 Sigma 相关的失调或疾病的方法，该方法包括向受试者施用有效量的 Sigma 调节化合物。本发明还包括预防、治疗或改善有需要的受试者的西格玛相关紊乱或疾病的方法，该方法包括向受试者施用有效量的西格玛调节化合物，进一步包括施用有效量的抑制泛素蛋白酶体系统（UPS）和/或自噬存活途径的化合物。